Drug Trial Radar · NCT00038662
Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure
Last checked: Nov 20, 2026Latest source record: Aug 15, 2006 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
200
Actual
Start
May 2002
Primary completion
Not stated
Sponsor
- Lead sponsor
- AbbottIndustry
- Sponsor type
- Industry
- First posted
- Jun 4, 2002
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- Male only, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this phase II, randomized, double-blind placebo controlled, multi-center study is to evaluate the safety and efficacy of 10 mg atrasentan in hormone naive subjects as measured by rate of rise in the PSA (primary objective).
Conditions
- Prostatic Neoplasms
Interventions
AtrasentanDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the safety and efficacy of 10mg atrasentan in hormone naive subjects, as measured by the rate of rise in PSA.
Locations
40 sites in 2 countries. Site status is shown where the registry gives one.
Urology Centers Of Alabama
Homewood, Alabama
Alaska Clinical Research Center, LLC
Anchorage, Alaska
Arkansas Urologial Associates, PA
Little Rock, Arkansas
San Diego Urology Center
La Mesa, California
Western Clinical Research Inc
Torrance, California
Georgetown University Medical Center
Washington D.C., District of Columbia
Clinical Physiology Associates
Fort Myers, Florida
Southeastern Urological Center, PA
Tallahassee, Florida
Northwestern University
Chicago, Illinois
Johns Hopkins Oncology Center
Baltimore, Maryland
Sheldon Freedman MD
Las Vegas, Nevada
VA Medical Center(111)
Reno, Nevada
Nevada Urology Associates
Reno, Nevada
Carolinas Medical Centre
Charlotte, North Carolina
Cleveland Clinic Foundation
Cleveland, Ohio
Urologic Specialists Of Oklahoma, Inc.
Tulsa, Oklahoma
Oregon Urology Specialists
Eugene, Oregon
Urological Assoc. of Lancaster
Lancaster, Pennsylvania
University Of Pittsburgh
Pittsburgh, Pennsylvania
Center for Urologic Care
West Reading, Pennsylvania
Ntouch Research Corporation
Dallas, Texas
Salt Lake Research
Salt Lake City, Utah
Jeffrey Frankel, M.D.
Seattle, Washington
University of Washington Medical Center
Seattle, Washington
Tom Baker Cancer Center
Calgary, Alberta, Canada
Cross Cancer Institute
Edmonton, Alberta, Canada
Cal Andreou, MD
Surrey, British Columbia, Canada
Can-Med Medical Research Inc
Victoria, British Columbia, Canada
Bruce W. Palmer Urology Inc.
Kentville, Nova Scotia, Canada
The Male Health Centres
Barrie, Ontario, Canada
Burlington Professional Centre
Burlington, Ontario, Canada
Hamilton & District Urology Association
Hamilton, Ontario, Canada
London Health Sciences Centre
London, Ontario, Canada
Quest Clinical Trials
Markham, Ontario, Canada
Guardian Medical Arts Bldg.
North Bay, Ontario, Canada
Jack Barkin, MD
North York, Ontario, Canada
The Male Health Centres
Oakville, Ontario, Canada
Sunnybrook &Women's College Health Sciens Center
Toronto, Ontario, Canada
Hopital Notre-Dame
Montreal, Quebec, Canada
Chuq Pavillon Hotel-Dieu
Québec, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.